Hiromi Matsubara
Hiromi Matsubara is an expert in Cardiology at Okayama Medical Center (Japan). As of July 2026, ScienceLeadR ranks Hiromi Matsubara in the top 1% of experts worldwide for Hypertension and Hypertension, Pulmonary. Hiromi Matsubara has authored 238 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 664 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 238
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Early parenteral prostacyclin therapy enables near-normal haemodynamics and treatment de-escalation in patients with haemodynamically severe pulmonary arterial hypertension. PMID 42463271 — epoprostenol, hypertension, respiration, pulmonary arterial hypertension, therapeutics | Eur Respir J | 2026 | 0 |
| PVRI-GoDeep-A Global Meta-Registry at the Crossroads of Heart and Lung. PMID 41876955 — registries, lung, hypertension, pulmonary, heart, physiological phenomena, diagnosis, therapeutics | Compr Physiol | 2026 | 0 |
| Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment. PMID 41406504 — registries, hypertension, comorbidity, mortality, hypertension, pulmonary, biomedical research, obesity, sex, therapeutics | EBioMedicine | 2025 | 0 |
| Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis. PMID 40772955 — registries, phosphodiesterase 5 inhibitors, hypertension, pulmonary, phosphoric diester hydrolases, critical care, cyclic nucleotide phosphodiesterases, type 5, therapeutics, hemodynamics, lung diseases, interstitial | Am J Respir Crit Care Med | 2025 | 0 |
| Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry. PMID 40636151 — registries, hypertension, hypertension, pulmonary, therapeutics, survival rate | Pulm Circ | 2025 | 2 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
LeadR Networks
Main global connection map